Related Experiment Video

Updated: Jul 10, 2026

High-Throughput Small Molecule Drug Screening For Age-Related Sleep Disorders Using Drosophila melanogaster
05:59

High-Throughput Small Molecule Drug Screening For Age-Related Sleep Disorders Using Drosophila melanogaster

Published on: October 20, 2023

Potential pharmacokinetic basis for zolpidem dosing in children with sleep difficulties

J L Blumer1, M D Reed, F Steinberg

  • 1Department of Pediatrics, Rainbow Babies and Children's Hospital, Case Western Reserve University, Cleveland, Ohio, USA. Jeffrey.Blumer@UHhospitals.org

Clinical Pharmacology and Therapeutics
|October 25, 2007
PubMed

Insights

This study evaluated zolpidem pharmacokinetics in children with insomnia. A dose of 0.25 mg/kg is recommended for future pediatric zolpidem efficacy studies.

Area of Science:

  • Pediatric pharmacology
  • Sleep medicine
  • Clinical pharmacokinetics

Background:

  • Insomnia is a prevalent sleep disorder in children.
  • Limited pharmacokinetic data exists for zolpidem in pediatric populations.
  • Understanding zolpidem's behavior in children is crucial for safe and effective treatment.

Purpose of the Study:

  • To assess the pharmacokinetics of zolpidem in children with insomnia.
  • To determine the influence of dose and age on zolpidem's pharmacokinetic parameters.
  • To provide recommendations for future pediatric zolpidem dosing.

Main Methods:

  • Open-label, dose-escalation study involving 21 children aged 2-18 years.
  • Participants received single doses of zolpidem (0.125, 0.25, or 0.50 mg/kg).
  • Pharmacokinetic parameters (Cmax, AUC, half-life) were measured over nine intervals; pharmacodynamics assessed via polysomnography and actigraphy.

Main Results:

  • Zolpidem exposure (Cmax, AUC) increased linearly with dose.
  • Age significantly affected AUC, half-life, and mean residence time, with decreased clearance in older children.
  • Pharmacodynamic measures were not significantly correlated with pharmacokinetic estimates.

Conclusions:

  • Zolpidem exhibits dose-dependent pharmacokinetics in children.
  • Age influences zolpidem's absorption and elimination.
  • A pediatric dose of 0.25 mg/kg is suggested for further efficacy trials.

More Related Videos

Polygraphic Recording Procedure for Measuring Sleep in Mice08:45

Polygraphic Recording Procedure for Measuring Sleep in Mice

Published on: January 25, 2016

Measuring Neural Mechanisms Underlying Sleep-Dependent Memory Consolidation During Naps in Early Childhood08:20

Measuring Neural Mechanisms Underlying Sleep-Dependent Memory Consolidation During Naps in Early Childhood

Published on: October 2, 2019

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Sedatives and Hypnotics: Overview01:23

Sedatives and Hypnotics: Overview

Sedatives are drugs that alleviate anxiety, while hypnotics induce sleep. Both classes of medication suppress neuronal activity, leading to a calming effect for sedatives and facilitating sleep for hypnotics.
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...